Ivana Magovčević-Liebisch

Dr. Magovčević-Liebisch is President and Chief Executive Officer of Draig Therapeutics. She is an accomplished pharmaceutical and biotechnology executive with over 25 years of senior management experience, leading companies across a wide range of strategic and operational functions.

Before joining Draig, Dr. Magovčević-Liebisch served as President and CEO of Vigil Neuroscience, a company she founded, built and led until its acquisition by Sanofi in August 2025. Under her leadership, Vigil evolved from inception with early preclinical assets through IPO to a clinical-stage organization within 18 months. She also raised more than $350 million while advancing Vigil’s lead candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer’s disease.

Dr. Magovčević-Liebisch holds a Ph.D. in Genetics from Harvard University and received her J.D. in High Technology Law from Suffolk University Law School. She graduated from Wheaton College with a B.A. in Biology and Chemistry.